一氧化氮合酶(NOS)的表达增加与不同的癌症,如宫颈癌,乳房,肺,大脑,和脊髓。已经提出抑制NOS活性作为预防乳腺癌的潜在工具。L-硝基精氨酸甲酯(L-NAME)的抗肿瘤治疗作用,NOS抑制剂,目前正在研究使用体内模型。我们假设L-NAME通过调节细胞死亡和增殖来延缓乳腺癌的进展,从而显示出抗肿瘤作用。和血管生成。我们通过施用L-NAME(每天30mg/kg,腹膜内)每三天注射一次,持续五周,用于7,12-二甲基苯并[a]蒽(DMBA)诱导的乳腺肿瘤的大鼠模型。亚硝酸盐阴离子的浓度,多胺,丙二醛,NH4+水平,与DMBA大鼠相比,DMBAL-NAME治疗的大鼠血液中的精氨酸酶活性降低。死亡率,肿瘤数量,体重,和音量,以及乳腺癌的组织病理学分级也显著降低。此外,L-NAME治疗显示肿瘤形成延迟,以及与仅施用DMBA的大鼠相比的体重。总之,我们的数据显示,L-NAME是治疗乳腺癌的一种有前途的抗癌剂,这可能导致未来抗肿瘤治疗工具的发展。
Increased expression of nitric oxide synthase (NOS) is associated with different cancers such as cervical, breast, lung, brain, and spinal cord. Inhibition of NOS activity has been suggested as potential tool to prevent breast cancer. The anti-tumor therapeutic effect of L-nitro arginine methyl ester (L-NAME), NOS inhibitor, using in vivo models is currently under investigation. We hypothesized that L-NAME will show an anti-tumor effect by delaying a progression of breast cancer via a modulation of cell death and proliferation, and angiogenesis. We used a novel model of anti-cancer treatment by the administration of L-NAME (30 mg/kg in a day, intraperitoneal) injected every third day for five weeks to rat model of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast tumor. Concentrations of nitrite anions, polyamines, malondialdehyde, NH4+ levels, and arginase activity in the blood were decreased in DMBA + L-NAME-treated rats compared with DMBA rats. The mortality rates, tumor number, weight, and volume, as well as the histopathological grade of breast cancer were also significantly reduced. In addition, L-NAME treatment showed a delay in tumor formation, and in body weight compared with rats administrated only with DMBA. In conclusion, our data show that L-NAME is a promising anti-cancer agent to treat breast cancer, which can lead to development of anti-tumor therapeutic tools in future.